Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
|
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
来源
PROSTATE | 2020年 / 80卷 / 01期
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [41] INTEGRATION OF POLYGENIC RISK SCORE (PRS) WITH MULTIPARAMETRIC MRI IN MEN AT RISK FOR CLINICALLY SIGNIFICANT PROSTATE CANCER
    Plym, Anna
    Madueke, Ikenna
    Naik, Sachin
    Penney, Kathryn L.
    Mucci, Lorelei A.
    Khorasani, Rhamin
    Kibel, Adam S.
    JOURNAL OF UROLOGY, 2023, 209 : E1045 - E1045
  • [42] Breast cancer risk assessment based on susceptibility genes and polygenic risk score in Vietnamese women
    Dao Nguyen Vinh
    Thanh Thi Ngoc Nguyen
    Tuan-Anh Nguyen Tran
    Phuoc-Loc Doan
    Van-Anh Nguyen Hoang
    Minh-Duy Phan
    Hoa Giang
    Hoai-Nghia Nguyen
    Hue Thi Nguyen
    Lan N. Tu
    BJC Reports, 2 (1):
  • [43] Improving a polygenic risk score (PRS) for breast cancer (BC) risk assessment in diverse ancestries
    Simmons, Timothy
    Hughes, Elisha
    Pruss, Dmitry
    Kucera, Matthew
    Roa, Benjamin
    Judkins, Thaddeus
    Younus, Adib
    Cummings, Shelly Ann
    Jammulapati, Srikanth
    Timms, Kirsten
    Kurian, Allison W.
    Pederson, Holly Jane
    Whitworth, Pat W.
    Wagner, Susanne
    Muzzey, Dale
    Lanchbury, Jerry S.
    Gutin, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Breast cancer risk assessment combined with a polygenic risk score in the general population for personalized screening
    Saghatchian, Mahasti
    Abehsera, Marc
    Sigal, Robert
    Gauthier, Emilien
    Helin, Valerie
    Villoing-Gaude, Laure
    Reyes, Cecile
    Rapinat, Audrey
    Gentien, David
    Golmard, Lisa
    Stoppa-Lyonnet, Dominique
    CANCER RESEARCH, 2021, 81 (04)
  • [45] Assessment of previously reported polygenic risk score for breast cancer in Peruvian women
    Zavala, Valentina A.
    Vidaurre, Tatiana
    Huang, Xiaosong
    Casavilca, Sandro
    Navarro, Jeannie
    Williams, Michelle A.
    Sanchez, Sixto E.
    Gelaye, Bizu
    Fejerman, Laura
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [46] Assessment of Body Mass Index, Polygenic Risk Score, and Development of Colorectal Cancer
    Chen, Xuechen
    Li, Hengjing
    Mandic, Marko
    Hoffmeister, Michael
    Brenner, Hermann
    JAMA NETWORK OPEN, 2022, 5 (12) : E2248447
  • [47] Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians
    Song, Sang Hun
    Kim, Eunae
    Jung, Yu Jin
    Kim, Hak-Min
    Park, Moon Soo
    Kim, Jung Kwon
    Lee, Hakmin
    Oh, Jong Jin
    Lee, Sangchul
    Hong, Sung Kyu
    Byun, Seok-Soo
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [48] Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese
    Hung, Sheng-Chun
    Chang, Li-Wen
    Hsiao, Tzu-Hung
    Wei, Chia-Yi
    Wang, Shian-Shiang
    Li, Jian-Ri
    Chen, I-Chieh
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [49] Polygenic Hazard Score for Prostate Cancer Risk Stratification: Validation in Additional Longitudinal Cohorts
    Tye, K.
    Huynh-Le, M. P.
    Fan, C. C.
    Berndt, S. I.
    Hamdy, F.
    Mills, I.
    Andreassen, O. A.
    Dale, A. M.
    Seibert, T. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E311 - E311
  • [50] Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians
    Sang Hun Song
    Eunae Kim
    Yu Jin Jung
    Hak-Min Kim
    Moon Soo Park
    Jung Kwon Kim
    Hakmin Lee
    Jong Jin Oh
    Sangchul Lee
    Sung Kyu Hong
    Seok-Soo Byun
    Scientific Reports, 13